Trial Profile
Open-label, Dose-escalation, Phase 1 Trial to Evaluate the Safety of VM202RY Gene Medicine Injected Into Myocardial Territory With Incomplete Revascularization During Coronary Artery Bypass Graft in Patients With Ischemic Heart Disease
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Aug 2019
Price :
$35
*
At a glance
- Drugs Donaperminogene seltoplasmid (Primary)
- Indications Ischaemic heart disorders
- Focus Adverse reactions
- Sponsors Helixmith; ViroMed
- 26 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 26 Aug 2011 New trial record